Gilead Sciences, Inc. (GILD:NASDAQ) closed at $159.24 on October 15, 2026, up 3.71% on the day. The stock trades 0.8% below its 52-week high of $160.49 and 39.7% above its 52-week low of $114.02. Over the past year, it gained 29.8%. Gilead Sciences, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| +2.07% | +4.95% | +14.34% | +13.01% | +29.79% |
In 252 trading sessions since October 14, 2025, GILD closed higher on 125 days (50%). Its best day was February 11, 2026 (+5.82%) and its worst was July 10, 2026 (-3.72%). It never moved 10% or more in a single session.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other product...
Find more stocks like GILD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.